

Dated: August 11th, 2008

VENUS LAUNCHES ITS FOURTH RESEARCH PRODUCT _

The Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name “TOBRACEF” in Domestic Market for the first time globally.

The **Drug Controller General of India** had accorded its approval to Venus Remedies for launch of the fourth innovative product developed by Venus Research Centre, after completion of its multi-centred Phase III Clinical Trials and all related studies in March 2008. ***Tobrcef, a brand launched by the marketing division of the Company***, is a god send for APE/Cystic Fibrosis patients being the only solution for the treatment of life threatening infections caused by P. Aeruginosa / MRSA in these patients.

The PSD division is targeting to fast penetrate the INR 2 billion domestic market and is expected to build this brand as a segment leader within 2 years of its launch. There are approximately 50 patent applications in process in 50 countries across the globe for this wonderful product and the Company is in talks for out-licensing of this product in US and other regulated markets of the world.

Released By

For VENUS REMEDIES LIMITED

(SONIA MALHOTRA)

DGM (Corporate Planning & Communications)

mis@venusremedies.com

093163-11025